GE HealthCare Wants to Buy the Bullets for Its Own Guns
GE HealthCare is reportedly in talks to buy radiopharmaceutical developer Sofie Biosciences for ~$1 billion. The deal would let the scanner giant own both the cameras and the film, positioning it at the center of the booming theranostics market.
The Scanner Company Wants to Sell the Ammo, Too
Imagine owning every movie theater in town but not the movies. You'd control the seats, the screens, the popcorn machines. But without films to show, those theaters are just expensive real estate. That's roughly the position GE HealthCare is trying to fix.
Reuters reported this week that GE HealthCare is in talks to acquire Sofie Biosciences, a radiopharmaceutical developer, for approximately $1 billion. The deal isn't done yet, and could still fall apart. But if it closes, it would mark a fundamental shift in how GE thinks about its imaging business.
GE HealthCare makes the scanners. Sofie makes the radioactive chemicals you inject into patients so those scanners actually have something to see. Buying Sofie would mean GE controls both the camera and the film.
Who Is Sofie, Anyway?
Sofie Biosciences was founded in 2008 as a spinout from UCLA and Caltech. Based in Dulles, Virginia, the company has quietly become one of the more significant players in PET imaging agents (the radioactive tracers used in PET scans to light up cancer and other diseases).
The scale is real: Sofie manufactures more than 567,000 doses annually for partners and customers. That's not a startup playing around in a lab; that's a commercial operation with serious throughput.
Sofie's most interesting assets sit in its pipeline. The company licensed a class of molecules called FAPI tracers from the University of Heidelberg back in 2019. These tracers target a protein found in the connective tissue surrounding many tumors, which means they could detect cancers that current PET tracers miss. Two lead compounds, FAPI-46 and FAPI-74, are the crown jewels.
And here's where it gets interesting: GE HealthCare and Sofie already signed an exclusive global licensing deal in October 2023 to develop and commercialize those exact FAPI tracers. So GE has been dating this company for three years. Now it wants to put a ring on it.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
GE HealthCare's strategic logic follows one of the oldest business models in capitalism. Sell the razor cheaply, make your money on the blades. Or in this case: sell PET scanners, then sell the radioactive tracers hospitals need to run them.
Right now, GE's pharmaceutical diagnostics business supplies some imaging agents. But owning Sofie would deepen that portfolio significantly, shifting GE's revenue mix toward recurring, consumable-like sales instead of relying solely on big one-time equipment purchases.
Think of it like a printer company acquiring an ink manufacturer. Every scan needs a fresh dose of tracer. Hospitals don't buy a PET scanner and then stop spending; they buy tracers week after week, patient after patient. That's the kind of revenue stream that makes CFOs smile.
The Price Tag Raises Eyebrows
A billion dollars is a lot of money for a private company that reportedly was valued at up to $550 million as recently as 2024. That's nearly double the prior valuation in roughly two years.
Analyst commentary has zeroed in on this gap. The key question: does owning Sofie create meaningfully more value than simply licensing its technology, which GE was already doing? The acquisition premium has to be justified by incremental cash flow that the licensing deal alone couldn't deliver.
If the deal closes, it would be another step in GE HealthCare's growing acquisition strategy since spinning off from General Electric. The company picked up MIM Software in 2024 to add imaging analytics, and it announced plans to acquire NMP to expand radiopharmaceutical capabilities in Japan. A pattern is forming: GE is building a precision-care empire, one acquisition at a time.
The Theranostics Gold Rush
Zoom out, and this deal is really about a bigger trend: theranostics, the convergence of diagnosis and therapy into a single platform. The idea is beautifully simple. Use a radioactive tracer to find the tumor (that's the "diagnostics" part), then swap in a therapeutic version of the same molecule to treat it (that's the "therapy" part). Same target, same biology, but one version takes a picture and the other delivers radiation directly to cancer cells.
Novartis is the current king of this space. Its two radioligand therapy products, Lutathera and Pluvicto, generated a combined $2.8 billion in 2025 revenue. The broader radiopharmaceutical theranostics market is estimated at roughly $2.5 to $3.3 billion, depending on who's counting and how they define the boundaries, with projections reaching $4.5 billion by the early 2030s.
Every major pharma company is circling this space. The appeal is obvious: targeted therapy that can be visualized, measured, and personalized in ways that traditional drugs simply can't match. Nuclear medicine is evolving from "take a picture of disease" to "take a picture of the biology, then deliver therapy directly to that biology."
GE HealthCare may not be building therapeutic radiopharmaceuticals yet. But by owning diagnostic tracers and the scanners that use them, it's positioning itself as the essential infrastructure layer for the entire theranostics workflow. You can't treat what you can't see, and GE wants to own the "seeing" part completely.
What Happens Next
Reports suggest an announcement could come as soon as next week, though nothing is confirmed. GE HealthCare declined to comment, while Sofie could not be reached for comment.
The deal still carries risk. Integration of a radiopharmaceutical company into a device-and-diagnostics giant is complicated; manufacturing radioactive tracers involves specialized supply chains, short shelf lives (some tracers decay within hours), and regulatory complexity that's very different from building CT scanners.
But the strategic direction is unmistakable. GE HealthCare has told investors it's targeting mid-single-digit organic revenue growth through 2028, powered by innovation, partnerships, and M&A. Sofie fits that playbook perfectly.
If this deal closes, it sends a clear signal to the rest of the industry: the companies that make imaging hardware aren't content to just sell equipment anymore. They want to own the molecules, the software, and the clinical workflow. The line between device company and pharma company is getting blurrier by the quarter.
And in theranostics, being blurry might just be the sharpest strategy of all.
Clinical & Regulatory4 min read
Lutathera Just Got Its First Copycat. Radioligand Therapy Will Never Be the Same.
The FDA just approved the first-ever generic radioligand drug, a copycat of Novartis' blockbuster Lutathera. It's a regulatory first that could crack open pricing and competition in one of oncology's most complex (and expensive) drug categories.
